Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 2/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17339944 | 0.89 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3HRH3HTR2C | |
| SCHEMBL10260953 | 0.89 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3HRH3HTR2C | |
| SCHEMBL10077967 | 0.83 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3HRH3KMT2A | |
| SCHEMBL22839032 | 0.83 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL17128677 | 0.83 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3HRH3MGLL | |
| SCHEMBL20147889 | 0.82 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HRH3KMT2A | |
| SCHEMBL20068832 | 0.82 | HRH3 (0.50) | SLC6A4SLC6A2SLC6A3HRH3MGLL | |
| SCHEMBL20176333 | 0.82 | SLC6A4 (0.38) | SLC6A4SLC6A2SLC6A3HTR2CHTR2B | |
| SCHEMBL13184995 | 0.81 | SLC6A2 (0.55) | SLC6A4SLC6A2SLC6A3MGLLSCN9A | |
| SCHEMBL7235082 | 0.80 | SLC6A2 (0.67) | SLC6A4SLC6A2SLC6A3MGLLABHD6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9643970-B2 | Substituted imidazo [1,5-a]pyrazines as PDE9 inhibitors | H. LUNDBECK A/S (DK) | 2017-05-09 | — | — | US | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-9212147-B2 | Dihydroxy aromatic heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-12-15 | — | — | US | disclosed |
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | SUNDIA MEDITECH COMPANY, LTD. (CN) | 2015-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150274736-A1 | PDE9i with imidazo pyrazinone backbone | PDE9A, PDE5A, PDE12 | SLC6A4 1094/4885SLC6A2 903/4885SLC6A3 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.